TissueGen Inc.

With drug-eluting stents under siege, entrepreneurs push to develop a stent that won’t overstay its welcome. Just three years ago bioabsorbable stents seemed to be more of a "nice to have" than a "nee

Expanding the inventory of deliverable drugs 2110 Research Row Suite 527 Dallas, TX 75235 Phone: (214) 351-1922 Fax: (775) 855-4771 Web Site: www.tissuegen.com Contact: Keith Brown, President & CEO

A preview of the emerging health care companies profiled in the current issue of START-UP: Windhover’s Review of Emerging Medical Ventures This month's profile groups: Treating Traumatic Brain Injury

The advent of drug-eluting stents has increased the partnering visibility for companies with biocoatings. Ten years ago, SurModics Inc. , one of the few sizeable "pure play" companies in the biocoa